Robert Azelby, EVP & Chief Commercial Officer at Juno Therapeutics, Inc. (JUNO), sold 4,157 shares at $85.55 ($356K) on 2018-02-12, disclosed to the SEC on 2018-02-14.
Scheduled sale ($356k) by EVP & Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| JUNO | SELL | 2018-02-09 | $600K | — | Filing → |
| JUNO | SELL | 2018-02-02 | $715K | — | Filing → |
| JUNO | SELL | 2018-01-24 | $17.7M | — | Filing → |